Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces substantial, dose-dependent weight loss in adults with obesity (mean 15-21% over 72 weeks) and superior glycemic control compared to placebo and other GLP-1 agonists.
Tirzepatide is a once-weekly injection that targets two gut hormones (GIP and GLP-1) to reduce appetite and improve blood sugar. In clinical trials, it led to an average weight loss of 15-21% over 72 weeks, significantly outperforming placebo and other GLP-1 drugs like Semaglutide. It is prescribed for adults with obesity (BMI ≥30, or ≥27 with comorbidities) and requires a slow dose escalation to manage gastrointestinal side effects.
During 72 weeks treatment, Tirzepatide-treated participants achieved an average weight loss from baseline of 15.0, 19.5 and 20.9% at doses of 5 mg, 10 mg and 15 mg, respectively, compared to merely 3.1% in the placebo group [54].
Why this rating
Based on multiple Phase 3 RCTs (SURPASS, SURMOUNT) with large sample sizes and clear statistical significance.
Source
Pharmacotherapy for chronic obesity management: a look into the future
Mariana Abdel-Malek et al. · Internal and Emergency Medicine · 2023
DOI 10.1007/s11739-023-03237-4
More from this paper
- Cagrilintide, a long-acting amylin analogue, produces dose-dependent weight loss in adults with obesity, with the highest dose (4.5 mg) showing greater weight loss than Liraglutide 3.0 mg.Good
- Setmelanotide, a melanocortin-4 receptor (MC4R) agonist, produces significant weight loss in patients with specific genetic obesity disorders (POMC, LEPR, or PCSK1 deficiency).Good
- Combination therapy of Cagrilintide (amylin analogue) and Semaglutide (GLP-1 agonist) produces synergistic weight loss, with the 2.4 mg Cagrilintide dose achieving 17.1% weight loss over 20 weeks.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →